CANscript – The innovative new test for personally suited oncologic treatment
CANscript is a unique and powerful diagnostic platform that provides strong reaction prediction for personally suited treatment.
This is a test that is entirely different test from genetic/genome testing.
The genome testing can assist the doctor in making decisions regarding the different treatment options by identifying genes and genetic deviations in order to classify the patient according to a specific populationsegment or the type of tumor and recommending treatment based on results of that population, without a great measure of certainty that the treatment will work for that specific patient.
This testing is also unable to capture the full biological composition of the local tumor, limiting its ability to reliably predict the clinical outcome.
The genomic cancer profile categorizes patients on the basis of identification of genetic mutations. Other functional platforms manipulate and distort the growth tissue for purposes of assessment and as a result the level of correlation with the patient's reaction is low.
The CANscript test was developed by laboratories in Boston in collaboration with Harvard University Medical School, the Dana-Farber Cancer Institute, and the Broad Institute at MIT, together with other respected institutions in the US and India.
The test is based on a biopsy taken from the patient and sent as fresh, living tissue to the Boston laboratory within 24 hours.
In the test itself, a series of different treatments requested by the doctor are tried on the tissue with 90% accuracy in predicting the success of the treatment. By way of clarification, as of today most treatments are given with only a 20% chance of success.
CANscript uses the biology of the patient by duplicating the unique natural microenvironment of the tumor to predict the reaction of the patient to a specific treatment in real time and to provide true customization of the clinical results. The unique platform provides strong personalized reaction predictions – with especially high correlation with the clinical results– in order to decide on the choice of specific treatment for the oncology patient.
This complicated duplication process is critical, since the spatial distribution of the cancerous cells and the stroma cells within the tumor's microenvironment can influence spreading, diagnosis, morphology, and other cellular functions, and ultimately change the prediction of the clinical reaction.
The platform makes use of a sophisticated algorithm with verified clinical data in order to provide a prediction regarding each patient's treatment.
The platform challenges the growth tissue with many combinations of medications in the system that surrounds the microenvironment of the tumorin order to decide on the appropriate medication combinations to make treatment decisions by the doctors possible in real time.
During the biopsy growth tissue is removed along with 10 ml of blood. Afterwards at the laboratory in Boston a variety of medications are tested and an attempt is made to duplicate the patient's reactions to these medications.
The resulting data are input into the advanced data of the algorithm. The advanced and verified data of Canscript are for the purpose of providing an accurate prediction for each patient tested.
The output of the algorithm is M – a grade for each treatment that was tested – that predicts the clinical reaction to that treatment.
An M grade of 26 and up indicates that the treatment is likely to produce a reaction.
An M grade of 25 or less indicates that the treatment is likely to be less effective.
90% correlation with clinical results in published data. The strong predictions of CANscript matched actual clinical results over 90% of the time.
The ability to accurately predict how a cancer patient will react to treatment can provide confidence and hope to both the patient and the doctor. Effective treatment can prolong the patient's life while dramatically improving his or her quality of life.
The results predict which treatments are very likely to work for a specific patient and identify treatments that are probably not effective for the patient. Customized medicine uses information specific to the unique patient in order to inform the doctors which treatment decisions are most optimal for that person, opening the door to improved accuracy in choice of treatment, facilitating the avoidance of less effective treatments, and offering an opportunity for the improvement of the patient's clinical results.
The time required until results are available is between 8 and 10 days.
For whom is this test suitable?
Colon cancer, Breast cancer, Ovarian cancer, Stomach cancer, Pancreatic cancer, Head and neck cancer, GBM brain tumors, Cancer of the liver, Acute myeloid leukemia, Chronic myeloid leukemia, Prostate cancer, Lung cancer (NSCLC not including squamous cell carcinoma), Esophageal cancer, Cervical cancer.